Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease (CKD). Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

Authors of a recent review explored the complex relationship between CKD, COVID-19, and anemia and offered practice points based on clinical experience. Patients with chronic kidney disease (CKD) ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Let's start with what causes anemia of ...

Treatment with vadadustat was noninferior to darbepoetin alfa in correcting and maintaining Hb levels in adults with incident dialysis-dependent CKD. The Food and Drug Administration (FDA) has ...

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

Sotagliflozin, a dual sodium-glucose cotransporter 1 and 2 inhibitor, rapidly improves hemoglobin levels in patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease (CKD), ...

The optimal target hemoglobin level for anemic patients with chronic kidney disease (CKD) is controversial. Two new randomized trials, both supported by makers of erythropoietin and both conducted in ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the ...